乳腺癌中的人类表皮生长因子受体2 (HER2) 状态:实践要点和挑战
Natthawadee Laokulrath1,2, Mihir Gudi2, Syed Ahmed Salahuddin3
1Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Histopathology
|June 7, 2024
概括
精确的人体表皮生长因子受体2 (HER2) 的解释对于乳腺癌治疗选择至关重要. 随着HER2评分挑战的不断变化,特别是HER2低的病例,需要更新准则,以准确地对患者进行分类.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 生物标记分析 生物标记分析
背景情况:
- 人体表皮生长因子受体2 (HER2) 阳性乳腺癌的治疗依赖于向疗法.
- 准确的HER2免疫组织化学 (IHC) 对于患者选择HER2向治疗至关重要.
- 针对HER2-低水平乳腺癌的HER2-向抗体-药物联合体的引入使IHC解释变得复杂.
研究的目的:
- 审查 HER2 IHC 解释中的不断变化的挑战.
- 为了解决 HER2 低乳腺癌分类带来的复杂性.
- 为标准化HER2 IHC评分提供实际建议.
主要方法:
- 对当前的HER2 IHC方法的文献综述.
- 在HER2评分中观察者间和实验室间变异性的分析.
- 对HER2-低状态的新兴诊断标准的讨论.
主要成果:
- 解释HER2 IHC面临挑战,特别是在区分HER2低病例 (0-1+) 时.
- 在不同的染色平台和病理学家之间存在显著的变化.
- 当前的评分系统可能无法充分捕捉新疗法资格的细微差别.
结论:
- 标准化的HER2 IHC解释对于有效的患者分层至关重要.
- 解决HER2评分的变化是必要的,以优化对HER2-阳性和HER2-低乳腺癌的治疗选择.
- 需要更新的指导方针和建议,以应对不断变化的HER2向疗法.
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K